Responsibilities of the Joint Research Committee Sample Clauses

Responsibilities of the Joint Research Committee. The JRC shall be responsible for (a) planning and supervising research and development under this Agreement, including establishing, reviewing and recommending modifications and updates to the Research Plans; (b) receiving and reviewing all data and other information obtained by either Party in connection with the Research Program and monitoring and reporting to the Parties on activities conducted pursuant to the Research Plans; (c) documenting and approving initiation and completion of each Research Project; (d) evaluating FTE requirements for the performance of the Research Plans; and (e) such other functions as expressly specified hereunder or as agreed by the Parties.
Sample 1Sample 2Sample 3See All (11)
AutoNDA by SimpleDocs
Responsibilities of the Joint Research Committee. The Joint Research Committee shall be responsible for making decisions in relation to the Research Program, including without limitation:
Sample 1Sample 2See All (5)
Responsibilities of the Joint Research Committee. During the pendency of the Research, the JRC shall be the primary vehicle for interaction between the Parties with respect to the Research. Without limiting the foregoing, the JRC shall be responsible for: (i) reviewing, approving and amending the Research Plan; (ii) recommending whether patents should be filed jointly or independently; (iii) reviewing and approving publications proposed by either Party with respect to results of the Research; (iv) monitoring the progress of Research; (v) reviewing patent filings; and (vi) selecting the specific Collaboration Compounds for recommendation to BMS for preclinical development. Each Party shall disclose to the other proposed agenda items in advance of each meeting of the JRC. All decisions by the JRC shall require agreement by the senior representative of each Party present at the meeting; provided, however, that if such representatives on the JRC cannot agree with respect to a particular issue, such issue shall be referred to the chief executive officer of Arris and the Senior Vice President, Drug Discovery at BMS for resolution. If such individuals cannot resolve the issues within thirty (30) days, the issues will be referred for binding arbitration pursuant to Section 11.11.
Sample 1
Responsibilities of the Joint Research Committee. The Joint Research Committee shall, among other things, (i) oversee the coordination, implementation and conduct of the Research Project; (ii) review the status and progress of the conduct of the Research Project; (iii) discuss, negotiate and approve the Quarterly Research Project Activities (as defined in Section 4(e) of this Agreement) and Quarterly Research Project Payment (as defined in Section 4(f) of this Agreement) for each Quarterly Research Project Period (as defined in Section 4(g) of this Agreement); (iv) determine if changes or additions are needed to the Research Project or the estimated time frames or estimated budget of the number and cost of the FTEs set forth in the Research Project Estimated Schedule and Budget; (v) approve and implement any changes or additions to the Research Project or the estimated time frames or estimated budget of the number and cost of the FTEs set forth in the Research Project Estimated Schedule and Budget; and (vi) facilitate on-going communications between the Parties.
Sample 1
Responsibilities of the Joint Research Committee. During the pendency of the Research, the JRC shall be the primary vehicle for interaction between the Parties with respect to the Research. Without limiting the foregoing, the JRC shall be responsible for: (i) reviewing, approving and amending the Research Plan; (ii) directing, managing and monitoring the progress of the Research; (iii) identifying to the parties that the criteria for particular changes to the Research Plan arising from changes in the Phase Transitions by RPR have been met; (iv) [*], and (v) reviewing and commenting upon (but not approving) the [*] of the Parties as provided in Article 7. The Research Plan shall contain the specific research objectives to be achieved according to the Phase Transition Criteria document attached hereto as Exhibit A, the specific responsibilities of the Parties, the timeline and budget for the Research, and the total number of FTEs to be devoted by each Party to the Research. Each Party shall disclose to the other proposed agenda items in advance of each meeting of the JRC.
Sample 1

Related to Responsibilities of the Joint Research Committee

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Responsibilities of the Parties 7.1. Rostelecom and the User bear responsibility for non-fulfillment or improper fulfillment of their responsibilities in the Agreement in accordance with the current law of the Russian Federation, (including the Regulations) and the Agreement.

  • Research Committee 2.2.1 Establishment and Functions of the RC. -------------------------------------

  • Steering Committee Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza. The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities:

  • Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).

  • Joint Project Team As soon as possible after the Effective Date, the Parties shall establish a joint project team (the “JPT”) which shall be initially responsible for the day-to-day operations of the Initial Target Program. The JPT shall also be responsible for the day-to-day operations of all other Collaboration Programs when they become ***Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. effective; provided, that if multiple JPTs are needed due to different Targets or disease areas, then the Parties may establish separate JPTs for different Collaboration Programs. The JPT shall be comprised of representatives from each of GSK and Adaptimmune with the appropriate scientific expertise with respect to the conduct of the Development Plans (and such representatives may vary depending on the relevant Project Phase) and shall meet on a monthly basis (or more or less frequently as agreed by the Parties) at Adaptimmune’s facilities, GSK’s facilities or via teleconference at such times as may be agreed by the Parties during the term of the applicable Collaboration Program. The JPT will report to the JSC and will be responsible for the day-to-day management of the conduct of the Development Plans including any non-material changes to the Development Plans, overseeing the conduct of experiments and reviewing data resulting from such experiments as set forth in the Development Plans, proposing amendments to the Development Plans, proposing new Development Plans to the JSC for new Collaboration Programs for JSC approval, discussing potential Lead Candidates and Development Candidates for proposal to the JSC. All decisions of the JPT on matters for which it has responsibility shall be made unanimously. In the event that the JPT is unable to reach a unanimous decision within ten (10) Business Days after it has met and attempted to reach such decision, then either Party may, by written notice to the other, have such issue submitted to the JSC for resolution in accordance with Section 4.5. Each Party will bear all expenses it incurs in regard to participating in all meetings of the JPT, including all travel and living expenses. Each JPT shall automatically cease to exist on completion of the relevant Collaboration Programs that it supports and exercise or expiry of all Collaboration Program Options applicable to such Collaboration Programs.

  • Project Team 6.1.1 The day-to-day responsibilities of the Parties with respect to this AGREEMENT shall be overseen by the PROJECT TEAM, which shall be responsible for deciding operational and scientific issues arising out of this AGREEMENT and unanimously agreeing in good faith with respect to the monitoring of the compliance with this AGREEMENT.

  • Joint Steering Committee [***] following the Effective Date [***], a joint steering committee (the “JSC”) will be established by the Parties to provide oversight and to facilitate information sharing between the Parties with respect to the activities under this Agreement.

  • Joint Development Committee The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Merck and BioLineRx, which shall have responsibility of coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such meeting, the BioLineRx Project Manager shall provide an update in writing to the Merck Project Manager, which update shall contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, the issue shall be elevated to the Head of Clinical Oncology for Merck and the Vice President of Medical Affairs or Business Development for BioLineRx.

  • Responsibilities of Adviser Without limiting the generality of the foregoing, the Adviser shall, during the term and subject to the provisions of this Agreement:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!